Contents to volume 47

July 1996 Volume 47 Number 1

Views & Reviews

1 Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop
I. Litvan, Y. Agid, D. Calne, G. Campbell, B. Dubois, R.C. Duvoisin, C.G. Goetz, L.I. Golbe, J. Grafman, J.H. Growdon, M. Hallett, J. Jankovic, N.P. Quinn, E. Tolosa, and D.S. Zee

10 Ten steps in characterizing and diagnosing patients with peripheral neuropathy
P.J. Dyck, P.J.B. Dyck, I.A. Grant, and R.D. Fealey

18 Axonal channelopathies: An evolving concept in the pathogenesis of peripheral nerve disorders
L. Gutmann and L. Gutmann

21 The world-wide burden of neurologic disease
D.C. Bergen

26 Neuroimaging in the emergency patient presenting with seizure
M.K. Greenberg, W.G. Barsan, and S. Starkman

Articles

33 Choosing the best needle for diagnostic lumbar puncture
D. Carson and M. Serpell

38 Psychological factors in the diagnosis and pathogenesis of stiff-man syndrome
P. Henningsen, U. Clement, J. Küchenhoff, F. Simon, and H.M. Meinck

43 Relative absence of psychopathology in benign essential blepharospasm and hemifacial spasm
C.E. Scheidt, B. Schuller, O. Rayki, G. Kommerell, and G. Deuschl

46 Sumatriptan in clinical practice: A 2-year review of 453 migraine patients
W.H. Visser, R.H.M. de Vriend, N.M.W.H. Jaspers, and M.D. Ferrari

52 Variation in migraine prevalence by race
W.F. Stewart, R.B. Lipton, and J. Liberman

60 Serum prolactin concentrations are elevated after syncope
E. Oribe, R. Amini, E. Nissenbaum, and B. Boal

63 Preictal pseudosleep: A new finding in psychogenic seizures
S.R. Benbadis, M.E. Lancman, L.M. King, and S.J. Swanson

68 Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures
R.H. Mattson, J.A. Cramer, J.F. Collins, and the Department of Veterans Affairs Epilepsy Cooperative Studies No. 118 and No. 264 Group

76 The prognostic value of the electroencephalogram in antiepileptic drug withdrawal in partial epilepsies
P. Tinuper, P. Avoni, R. Riva, F. Provini, E. Lugaresi, and A. Baruzzi

79 Epileptic forced thinking from left frontal lesions
M.F. Mendez, M.M. Cherrier, and K.M. Perryman

83 An assessment of nonconvulsive seizures in the intensive care unit using continuous EEG monitoring: An investigation of variables associated with mortality
G.B. Young, K.G. Jordan, and G.S. Doig

89 EEG-triggered echo-planar functional MRI in epilepsy
S. Warach, J.R. Ives, G. Schlaug, M.R. Patel, D.G. Darby, V. Thangaraj, R.R. Edelman, and D.L. Schomer

94 Isolated vertigo as a manifestation of vertebrobasilar ischemia
C.R. Gomez, S. Cruz-Flores, M.D. Malkoff, C.M. Sauer, and C.M. Burch

98 Childhood chronic inflammatory demyelinating neuropathies: Clinical course and long-term follow-up
Y. Nevo, A. Pestronk, A.J. Kornberg, A.M. Connolly, W.-C. Yee, I. Iqbal, and L.K. Shield

102 Eyeball pressure testing in the evaluation of serious bradyarrhythmias in Guillain-Barré syndrome
P. Flachenecker, W. Müllges, P. Wermuth, H.-P. Hartung, and K. Reiners

109 Gait of a deafferented subject without large myelinated sensory fibers below the neck
Y. Lajoie, N. Teasdale, J.D. Cole, M. Burnett, C. Bard, M. Fleury, R. Forget, J. Paillard, and Y. Lamarre

CONTENTS

115 Motor neuropathy due to docetaxel and paclitaxel
R.J. Freilich, C. Balmaceda, A.D. Seidman, M. Rubin, and L.M. DeAngelis

119 Sustained myoglobinuria: The presenting manifestation of dermatomyositis
M.R. Rose, J.T. Kissel, L.S. Bickley, and R.C. Griggs

123 Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: Disease activity resumes after stopping treatment
L. Durelli, M.R. Bongioanni, B. Ferrero, R. Ferri, D. Imperiale, G.B. Bradac, M. Bergui, M. Geuna, L. Bergamini, and B. Bergamasco

129 Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument
D.F. Cella, K. Dineen, B. Arnason, A. Reder, K.A. Webster, G. Karabatsos, C. Chang, S. Lloyd, F. Mo, J. Stewart, and D. Stefoski

140 The effect of spectrum bias on the utility of magnetic resonance imaging and evoked potentials in the diagnosis of suspected multiple sclerosis
P.W. O'Connor, C.M. Tansey, A.S. Detsky, A.I. Mushlin, and W. Kucharczyk

145 Subacute leukoencephalitis caused by CNS infection with human herpesvirus-6 manifesting as acute multiple sclerosis
D.R. Carrigan, D. Harrington, and K.K. Knox

148 Follow-up study of risk factors in progressive supranuclear palsy
L.I. Golbe, R.S. Rubin, R.P. Cody, J.M. Belsh, R.C. Duvoisin, C. Grosmann, F.E. Lepore, M.H. Mark, R.C. Sachdeo, J.I. Sage, and T.R. Zimmerman, Jr.

155 Risk of Parkinson's disease among first-degree relatives: A community-based study
K. Marder, M.-X. Tang, H. Mejia, B. Alfaro, L. Côté, E. Louis, J. Groves, and R. Mayeux

160 Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism
A. Ishikawa and S. Tsuji

166 Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
D. Knopman, L. Schneider, K. Davis, S. Talwalker, F. Smith, T. Hoover, S. Gracon, and the Tacrine Study Group

178 Category-specific difficulty naming with verbs in Alzheimer's disease
K.M. Robinson, M. Grossman, T. White-Devine, and M. D'Esposito

183 Language comprehension profiles in Alzheimer's disease, multi-infarct dementia, and frontotemporal degeneration
M. Grossman, M. D'Esposito, E. Hughes, K. Onishi, N. Biassou, T. White-Devine, and K.M. Robinson

190 The apolipoprotein E ϵ4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant
J.M. Olichney, L.A. Hansen, D. Galasko, T. Saitoh, C.R. Hofstetter, R. Katzman, and L.J. Thal

196 A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the ϵ4 allele
S. Mui, M. Briggs, H. Chung, R.B. Wallace, T. Gomez-Isla, G.W. Rebeck, and B.T. Hyman

201 Abnormalities of torsional fast phase eye movements in unilateral rostral midbrain disease
P. Riordan-Eva, M. Faldon, J.A. Büttner-Ennever, A. Gass, A.M. Bronstein, and M.A. Gresty

208 Speech timing in ataxic disorders: Sentence production and rapid repetitive articulation
W. Ziegler and K. Wessel

215 Clinical evidence of genetic anticipation in adult-onset idiopathic dystonia
J.T. Cheng, A. Liu, J. Wasmuth, B.P. Liu, and D. Truong

219 Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum
M.-T. Herrero, R. Levy, M. Ruberg, M.R. Luquin, J. Villares, J. Guillen, B. Faucheux, F. Javoy-Agid, J. Guridi, Y. Agid, J.A. Obeso, and E.C. Hirsch

225 CYP2D6 allelic frequencies in young-onset Parkinson's disease
M.S. Sandy, M. Armstrong, C.M. Tanner, A.K. Daly, D.A. Di Monte, J.W. Langston, and J.R. Idle

231 Spinal motoneuron excitability after acute spinal cord injury in humans
A.A. Leis, M.F. Kronenberg, I. Štětkářová, W.C. Paske, and D.S. Stokić

237 GM1b is a new member of antigen for serum antibody in Guillain-Barré syndrome
S. Kusunoki, M. Iwamori, A. Chiba, S. Hitoshi, M. Arita, and I. Kanazawa

243 Lethal infantile mitochondrial disease with isolated complex I deficiency in fibroblasts but with combined complex I and IV deficiencies in muscle
H.A.C.M. Bentlage, U. Wendel, H. Schägger, H.J. ter Laak, A.J.M. Janssen, and J.M.F. Trijbels

249 Decreased parvalbumin immunoreactivity in surviving Purkinje cells of patients with spinocerebellar ataxia-1
P.J.S. Vig, J.D. Fratkin, D. Desaiah, R.D. Currier, and S.H. Subramony

Brief Communications

254 Increased risk of dementia in mothers of Alzheimer's disease cases: Evidence for maternal inheritance
S.D. Edland, J.M. Silverman, E.R. Peskind, D. Tsuang, E. Wijsman, and J.C. Morris

256 A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease
G. Ramachandran, K. Marder, M. Tang, P.W. Schofield, M.R. Chun, D.P. Devanand, Y. Stern, and R. Mayeux

260 Patient awareness of seizures
D.E. Blum, J. Eskola, J.J. Bortz, and R.S. Fisher

264 Accuracy of reported family histories of essential tremor
K. Busenbark, P. Barnes, K. Lyons, D. Ince, F. Villagra, and W.C. Koller

266 Susac's syndrome: Neuropsychological characteristics in a young man
E. Ballard, J.F. Butzer, and J. Donders

269 Paraspinal muscle hematoma after electromyography
J.B. Caress, S.B. Rutkove, M. Carlin, S. Khoshbin, and D.C. Preston

272 Sodium channel accumulation in humans with painful neuromas
J.D. England, L.T. Happel, D.G. Kline, F. Gamboni, C.L. Thouron, Z.P. Liu, and S.R. Levinson

277 Traumatic occlusion of one limb of an intracranial arterial fenestration: An uncommon cause of stroke
W.I. Schievink, S.F. Hunter, W.R. Marsh, A.J. Aksamit, and C.R. Jack

Issues of Neurological Practice

279 US neurologists: Attitudes on the US health care system
S.P. Ringel, B.G. Vickrey, and T.L. Rogstad

Special Article

288 Practice Parameter: Neuroimaging in the emergency patient presenting with seizure—Summary Statement
Report of the Quality Standards Subcommittee of the American Academy of Neurology in cooperation with American College of Emergency Physicians, American Association of Neurological Surgeons, and American Society of Neuroradiology

Historical Neurology

292 The lunatic and his seizure
J. DeToledo, R.E. Ramsay, and C.A. Marsan

Works in Progress

294 Abstracts

Clinical/Scientific Notes

297 Easy therapeutical management of sumatriptan-induced daily headache
H. Göbel, H. Stolze, A. Heinze, and M. Dworschak

298 Spinal air embolism resulting from a party game
D.W. Barrett

299 Ictal radial and horizontal neglect
C.A.J. Boyle and A. Kirk

300 Aplastic anemia associated with ticlopidine
C.M. Shapiro and D. Walk

300 Cranial sinus thrombosis associated with essential thrombocythemia followed by heparin-associated thrombocytopenia
E.U. Walther, F.P. Tiecks, and R.L. Haberl

Correspondence

302 Cluster-tic syndrome
To the Editor: W.M. Mulleners and W.I.M. Verhagen. Reply from the Authors: R. Alberca and J.J. Ochoa

302 Psychogenic basilar migraine
To the Editor: A.K. Erdemoglu. Reply from the Authors: O. Devinsky

303 Fluoxetine and seizures
To the Editor: G.L. Gigli, M. Diomedi, A. Troisi, M.G. Marciani, and A. Pasini. Reply from the Authors: E. Favale, V. Rubino, P. Mainardi, and C. Albano

303 N30 in PD
To the Editor: P.M. Rossini. To the Editor: I. Ozaki, H. Shimamura, M. Baba, and M. Matsunaga. Reply from the Authors: P.A. Garcia, M.J. Aminoff, and D.S. Goodin

306 Ocular palsy and CIPD
To the Editor: V.K. Gupta. Reply from the Authors: J.C. Horton and J.G. Arroyo

306 Cerebellar timing process
To the Editor: R.J. Seitz. Reply from the Authors: M. Jueptner, C. Weiller, and H.C. Diener

307 Complex partial status
To the Editor: O.C. Cockerell, M.C. Walker, J.W.A.S. Sander, and S.D. Shorvon. Reply from the Authors: A. Krumholz, G.Y. Sung, E. Barry, G.K. Bergey, L.M. Grattan, and R.S. Fisher

308 Interferon ALFA
To the Editor: K. Ikeda and M. Kinoshitz. Reply from the Authors: A.D. Valentine, M.A. Pavol, and C.A. Meyers

309 Brain death
To the Editor: M.P. McQuillen. To the Editor: R.J. Hawley. Reply from the Author: E.F.M. Wijdicks

310 Cobalamin deficiency
To the Editor: E.J. Norman and C. Cronin. Reply from the Authors: R. Green and L.J. Kinsella

311 Albino visual pathway
To the Editor: G.S. Kosmorsky

311 Reading epilepsy
To the Editor: J.B. Green

311 SPECT in OPCA
To the Editor: M.I. Botez. Reply from the Authors: S. Gilman, R.T. St. Laurent, R.A. Koeppe, L. Junck, K.J. Kluin, and M. Lohman

Departments

313 Book Reviews

August 1996 Volume 47 Number 2

Editorial

317 Apolipoprotein E and cognitive decline in Alzheimer's disease
B.L. Plassman and J.C.S. Breitner

Views & Reviews

321 Spinal cord infarction: Etiology and outcome
W.P. Cheshire, C.C. Santos, E.W. Massey, and J.F. Howard, Jr.

331 X-linked malformations of neuronal migration
W.B. Dobyns, E. Andermann, F. Andermann, D. Czapansky-Beilman, F. Dubeau, O. Dulac, R. Guerrini, B. Hirsch, D.H. Ledbetter, N.S. Lee, J. Motte, J.-M. Pinard, R.A. Radtke, M.E. Ross, D. Tampieri, C.A. Walsh, and C.L. Truwit

Retraction

340 Retraction of: Orofacial motor control impairment in Parkinson's disease
J.H. Abbs, D.E. Hartman, and B. Vishwanat

Articles

341 Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation
D.M. Karussis, Z. Meiner, D. Lehmann, J.-M. Gomori, A. Schwarz, A. Linde, and O. Abramsky

347 Clinical concordance in sibling pairs with multiple sclerosis
N.P. Robertson, D. Clayton, M. Fraser, J. Deans, and D.A.S. Compston

353 Obsessive-compulsive disorder associated with brain lesions: Clinical phenomenology, cognitive function, and anatomic correlates
M.L. Berthier, J. Kulisevsky, A. Gironell, and J.A. Heras

361 A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine
J. Touchon, L. Bertin, A.J. Pilgrim, E. Ashford, and A. Bès

CONTENTS

366 Early CT signs in acute middle cerebral artery infarction: Predictive value for subsequent infarct locations and outcome
T. Moulin, F. Cattin, T. Crépin-Leblond, L. Tatu, D. Chavot, M. Piotin, J.F. Viel, L. Rumbach, and J.F. Bonneville

376 The stroke syndrome of cortical vein thrombosis
K. Jacobs, T. Moulin, J. Bogousslavsky, F. Woimant, I. Dehaene, L. Tatu, G. Besson, E. Assouline, and J. Casselman

383 Factors delaying hospital admission in acute stroke: The Copenhagen Stroke Study
H.S. Jørgensen, H. Nakayama, J. Reith, H.O. Raaschou, and T.S. Olsen

388 Factors predictive of stroke outcome in a rehabilitation setting
J.E. Ween, M.P. Alexander, M. D'Esposito, and M. Roberts

393 The value of intracranial pressure monitoring in acute hemispheric stroke
S. Schwab, A. Aschoff, M. Spranger, F. Albert, and W. Hacke

399 Cerebral metabolic differences between the severe and critical hypoperfused brain
J. van der Grond, L.M.P. Ramos, B.C. Eikelboom, and W.P.Th.M. Mali

405 Incidence of spontaneous intracerebral hemorrhage among Hispanics and non-Hispanic whites in New Mexico
A. Bruno, S. Carter, C. Qualls, and K.B. Nolte

408 Positive spontaneous visual phenomena limited to the hemianopic field in lesions of central visual pathways
M.S. Vaphiades, G.G. Celesia, and M.G. Brigell

417 Multiple cerebral lesions complicating therapy with interleukin-2
B. Illowsky Karp, J.C. Yang, M. Khorsand, R. Wood, and T.C. Merigan

425 Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
P.L. McGeer, M. Schulzer, and E.G. McGeer

433 Predictors of mortality in patients diagnosed with probable Alzheimer's disease
J.D. Bowen, A.D. Malter, L. Sheppard, W.A. Kukull, W.C. McCormick, L. Teri, and E.B. Larson

440 Apolipoprotein E ϵ4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease
A. Kurz, R. Egensperger, M. Haupt, N. Lautenschlager, B. Romero, M.B. Graeber, and U. Müller

444 Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease
J.H. Growdon, J.J. Locascio, S. Corkin, T. Gomez-Isla, and B.T. Hyman

449 Scrapie in mice deficient in apolipoprotein E or glial fibrillary acidic protein
J. Tatzelt, N. Maeda, M. Pekny, S.-L. Yang, C. Betsholtz, C. Eliasson, J. Cayetano, A.P. Camerino, S.J. DeArmond, and S.B. Prusiner

454 Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging
C.C. Meltzer, J.K. Zubieta, J. Brandt, L.E. Tune, H.S. Mayberg, and J.J. Frost

462 Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease
R.L. Albin, S. Minoshima, C.J. D'Amato, K.A. Frey, D.A. Kuhl, and A.A.F. Sima

467 Primary progressive apraxia in Pick's disease: A clinicopathologic study
T. Fukui, K. Sugita, M. Kawamura, J. Shiota, and I. Nakano

474 Reversible dementia in idiopathic hypoparathyroidism associated with normocalcemia
H.J. Stuerenburg, H.C. Hansen, A. Thie, and K. Kunze

477 Corpus callosum morphology in children with Tourette syndrome and attention deficit hyperactivity disorder
T.L. Baumgardner, H.S. Singer, M.B. Denckla, M.A. Rubin, M.T. Abrams, M.J. Colli, and A.L. Reiss

482 Contralesionally beating torsional nystagmus in a unilateral rostral midbrain lesion
C. Helmchen, S. Glasauer, K. Bartl, and U. Büttner

487 Headache in ambulatory HIV-1–infected men enrolled in a longitudinal study
E.J. Singer, J. Kim, B. Fahy-Chandon, A. Datt, and W.W. Tourtellotte

494 Headache in intracerebral hematomas
T.P. Melo, A.N. Pinto, and J.M. Ferro

500 Diurnal systolic blood pressure variability is the strongest predictor of early carotid atherosclerosis
D. Sander and J. Klingelhöfer

508 A primate genesis model of focal dystonia and repetitive strain injury: I. Learning-induced dedifferentiation of the representation of the hand in the primary somatosensory cortex in adult monkeys
N.N. Byl, M.M. Merzenich, and W.M. Jenkins

521 A longitudinal study of multimodal evoked potentials in patients following radiotherapy for nasopharyngeal carcinoma
L.-M. Tang, S.-T. Chen, W.-C. Hsu, and W.-M. Leung

526 Focal paresthesias with cervical magnetic stimulation
A.A. Cook and C.M. Epstein

529 Combined aerobic training and dichloroacetate improve exercise capacity and indices of aerobic metabolism in muscle cytochrome oxidase deficiency
T. Taivassalo, P.M. Matthews, N. De Stefano, N. Sripathi, A. Genge, G. Karpati, and D.L. Arnold

535 Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis
S. Sasaki and M. Iwata

541 Mutations of the noncoding region of the connexin32 gene in X-linked dominant Charcot-Marie-Tooth neuropathy
V.V. Ionasescu, Ch. Searby, R. Ionasescu, I.M. Neuhaus, and R. Werner

544 A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes
D.R. Scoles, M.E. Baser, and S.-M. Pulst

547 Late-onset G_{M2} gangliosidosis: Ashkenazi Jewish family with an exon 5 mutation (Tyr^{180}→His) in the Hex A α-chain gene
R. De Gasperi, M.A. Gama Sosa, S. Battistini, J. Yeretsian, S. Raghavan, N. Zelnik, E. Leshinsky, and E.H. Kolodny

552 Spontaneous multivessel cervical artery dissection in a patient with a substitution of alanine for glycine (G13A) in the α1(I) chain of type I collagen
S.A. Mayer, B.S. Rubin, B.J. Starman, and P.H. Byers

557 A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices
P. Calabresi, A. Siniscalchi, A. Pisani, A. Stefani, N.B. Mercuri, and G. Bernardi

562 Unprovoked seizures in children with febrile seizures: Short-term outcome
A.T. Berg and S. Shinnar

Brief Communications

569 Varicella-zoster virus DNA in CSF and arteries in delayed contralateral hemiplegia: Evidence for viral invasion of cerebral arteries
M. Melanson, C. Chalk, L. Georgevich, K. Fett, Y. Lapierre, H. Duong, J. Richardson, C. Marineau, and G.A. Rouleau

571 Incidence of amyotrophic lateral sclerosis in three counties in western Washington state
V. McGuire, W.T. Longstreth, Jr., T.D. Koepsell, and G. van Belle

573 Cutis verticis gyrata, underrecognized neurocutaneous syndrome
G.Y. Chang

576 Conduction aphasia in multiple sclerosis: A case report with MRI findings
P.A. Arnett, S.M. Rao, M. Hussain, S.J. Swanson, and T.A. Hammeke

579 Diagnosis of McArdle's disease by molecular genetic analysis of blood
M. El-Schahawi, S. Tsujino, S. Shanske, and S. DiMauro

581 Selective atrophy of type 1 muscle fibers in McArdle's disease
K.J. Felice, M.L. Grunnet, and A.A.F. Sima

583 Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS
Y. Ikejiri, E. Mori, K. Ishii, K. Nishimoto, M. Yasuda, and M. Sasaki

586 Dentatorubral-pallidoluysian atrophy proteins in lymphoblastoid cells
I. Yazawa, N. Nukina, Y. Ichikawa, and I. Kanazawa

588 Selective loss of small myelinated fibers in the lateral corticospinal tract due to midbrain infarction
S. Terao, M. Takahashi, M. Li, Y. Hashizume, H. Ikeda, T. Mitsuma, and G. Sobue

Special Articles

592 Assessment: Neuropsychological testing of adults. Considerations for neurologists
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

600 Practice Parameter: A guideline for discontinuing antiepileptic drugs in seizure-free patients—Summary Statement
Report of the Quality Standards Subcommittee of the American Academy of Neurology

Clinical/Scientific Notes

603 ApoE ε4 allele and cognitive decline in patients with Alzheimer's disease
T. Asada, T. Kariya, Z. Yamagata, T. Kinoshita, and A. Asaka

604 The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-β1b treatment in patients with multiple sclerosis
P. Rieckmann, F. Weber, A. Günther, and S. Poser

604 Recurrent Bell's palsy
J.B. English, E.W. Stommel, and J.L. Bernat

605 Occurrence of adrenocortical insufficiency in adrenomyeloneuropathy
W. Brennemann, W. Köhler, S. Zierz, and D. Klingmüller

605 Thyroxine exacerbates absence seizures in juvenile myoclonic epilepsy
T. Obeid, A. Awada, S. Al Rajeh, and A. Chaballout

606 HLA A24 in paraneoplastic cerebellar degeneration with anti-Yo antibody
M. Tanaka and K. Tanaka

607 Internalization of anti-Hu IgG is not Fcγ receptor mediated
A. Hormigo, C. Ball, and F. Lieberman

Correspondence

610 Periodic paralysis
To the Editor: S.E. Piwinski, Z. Windrow, and S. Newman. Reply from the Authors: I. Kantola and L. Tarssanen

610 Carotid dissection
To the Editor: A. Janati. Reply from the Authors: F. Thömke and M. Peters

611 MRI in Creutzfeldt-Jakob Disease
To the Editor: K. Takamiya, Y. Iwasaki, and M. Kinoshita. Reply from the Authors: S.S. Yoon and S. Chan

611 Tribute to Robert S. Dow, MD, PhD
To the Editor: R.E. Kramer

612 Oral sumatriptan
To the Editor: P. Tfelt-Hansen

612 Intracranial hypotension
To the Editor: M.S. Hochman and T.P. Naidich. Reply from the Author: B. Mokri

613 Focal suppression-burst
To the Editor: F. Cendes, E. Andermann, and F. Andermann. Reply from the Authors: D.R. Labar, S. Hosain, and R. Fraser

613 Genotypes and phenotypes
To the Editor: R.D. Currier and S.H. Subramony. Reply from the Author: R.N. Rosenberg

614 Neuro-Behçet's disease in Japan
To the Editor: K. Ikeda, M. Abe, Y. Iwasaki, and M. Kinoshita. Reply from the Authors: T. Devlin, L. Gray, N.B. Allen, A.H. Friedman, R. Tien, and J.C. Morgenlander

615 Docetaxel neuropathy
To the Editor: A. Pace, L. Bove, A. Pietrangeli, P. Innocenti, and B. Jandolo. Reply from the Authors: L.M. DeAngelis and R.J. Freilich

615 Chronic whiplash
To the Editor: A.J. Hudson

CONTENTS

September 1996 Volume 47 Number 3

Views & Reviews

617 The red ear syndrome
J.W. Lance

Articles

621 Patterns of involvement of facial muscles during epileptic and nonepileptic events: Review of 654 events
J.C. DeToledo and R.E. Ramsay

626 Reversible parkinsonism and cognitive impairment with chronic valproate use
C. Armon, C. Shin, P. Miller, S. Carwile, E. Brown, J.D. Edinger, and R.G. Paul

636 Diet and Parkinson's disease I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study
W. Hellenbrand, A. Seidler, H. Boeing, B.-P. Robra, P. Vieregge, P. Nischan, J. Joerg, W.H. Oertel, E. Schneider, and G. Ulm

644 Diet and Parkinson's disease II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study
W. Hellenbrand, H. Boeing, B.-P. Robra, A. Seidler, P. Vieregge, P. Nischan, J. Joerg, W.H. Oertel, E. Schneider, and G. Ulm

651 Visually and posturally mediated tilt illusion in Parkinson's disease and in labyrinthine defective subjects
A.M. Bronstein, L. Yardley, A.P. Moore, and L. Cleeves

657 Mechanical ventilation in stroke patients—is it worthwhile?
B. El-Ad, N.M. Bornstein, P. Fuchs, and A.D. Korczyn

659 Incontinence after stroke in a rehabilitation setting: Outcome associations and predictive factors
J.E. Ween, M.P. Alexander, M. D'Esposito, and M. Roberts

663 Further evidence on the link between migraine and neuroticism
N. Breslau, H.D. Chilcoat, and P. Andreski

668 Cytomegalovirus infection and Guillain-Barré syndrome: The clinical, electrophysiologic, and prognostic features
L.H. Visser, F.G.A. van der Meché, J. Meulstee, P.Ph. Rothbarth, B.C. Jacobs, P.I.M. Schmitz, P.A. van Doorn, and the Dutch Guillain-Barré Study Group

674 Complications of intravenous immune globulin treatment in neurologic disease
T.H. Brannagan III, K.J. Nagle, D.J. Lange, and L.P. Rowland

678 Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome
P.G. Bain, M. Motomura, J. Newsom-Davis, S.A. Misbah, H.M. Chapel, M.L. Lee, A. Vincent, and B. Lang

684 The prognostic impact of prior low grade histology in patients with anaplastic gliomas: A case-control study
E.J. Dropcho and S. Soong

690 Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France
T. Billette de Villemeur, J-P. Deslys, A. Pradel, C. Soubrié, A. Alpérovitch, M. Tardieu, J-L. Chaussain, J-J. Hauw, D. Dormont, M. Ruberg, and Y. Agid

696 Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging
G. Tedeschi, A. Bertolino, N. Lundbom, S. Bonavita, N.J. Patronas, J.H. Duyn, L. Verhagen Metman, T.N. Chase, and G. Di Chiro

705 A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease
L.J. Thal, A. Carta, W.R. Clarke, S.H. Ferris, R.P. Friedland, R.C. Petersen, J.W. Pettegrew, E. Pfeiffer, M.A. Raskind, M. Sano, M.H. Tuszynski, and R.F. Woolson

711 Specific tau variants in the brains of patients with myotonic dystrophy
P. Vermersch, N. Sergeant, M.M. Ruchoux, H. Hofmann-Radvanyi, A. Wattez, H. Petit, Ph. Dewailly, and A. Delacourte

718 Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease
J.M. Wilson, A.I. Levey, A. Rajput, L. Ang, M. Guttman, K. Shannak, H.B. Niznik, O. Hornykiewicz, C. Pifl, and S.J. Kish

727 Familial Creutzfeldt-Jakob disease with a five-repeat octapeptide insert mutation
E.J. Cochran, D.A. Bennett, L. Cervenáková, K. Kenney, B. Bernard, N.L. Foster, D.F. Benson, L.G. Goldfarb, and P. Brown

734 Polymorphism at codon 129 or codon 219 of *PRNP* and clinical heterogeneity in a previously unreported family with Gerstmann-Sträussler-Scheinker disease (PrP-P102L mutation)
P. Barbanti, G. Fabbrini, M. Salvatore, R. Petraroli, F. Cardone, B. Maras, M. Equestre, G. Macchi, G.L. Lenzi, and M. Pocchiari

741 Decreased receptor-mediated calcium response in prion-infected cells correlates with decreased membrane fluidity and IP_3 release
K. Wong, Y. Qiu, W. Hyun, R. Nixon, J. VanCleff, J. Sanchez-Salazar, S.B. Prusiner, and S.J. DeArmond

750 Association of HLA class II alleles in patients with juvenile myoclonic epilepsy compared with patients with other forms of adolescent-onset generalized epilepsy
D.A. Greenberg, M. Durner, S. Shinnar, S. Resor, D. Rosenbaum, I. Klotz, E. Dicker, M. Keddache, G. Zhou, X. Yang, and L. Altstiel

756 Is the intracellular pH different from normal in the epileptic focus of patients with temporal lobe epilepsy? A ^{31}P NMR study
W.-J. Chu, H.P. Hetherington, R.I. Kuzniecky, J.T. Vaughan, D.B. Twieg, R.E. Faught, F.G. Gilliam, J.W. Hugg, and G.A. Elgavish

761 Two divergent types of nerve pathology in patients with different P_0 mutations in Charcot-Marie-Tooth disease
A.A.W.M. Gabreëls-Festen, J.E. Hoogendijk, P.H.S. Meijerink, F.J.M. Gabreëls, P.A. Bolhuis, S. van Beersum, T. Kulkens, E. Nelis, F.G.I. Jennekens, M. de Visser, B.G.M. van Engelen, C. Van Broeckhoven, and E.C.M. Mariman

766 Paradoxically enhanced glucose production during exercise in humans with blocked glycolysis caused by muscle phosphofructokinase deficiency
J. Vissing, H. Galbo, and R.G. Haller

772 Isolation and characterization of a novel oligodendrocyte-specific protein
J.M. Bronstein, P. Popper, P.E. Micevych, and D.B. Farber

779 ApoE and CYP2D6 polymorphism with and without parkinsonism-dementia complex in the people of Chamorro, Guam
X. Chen, Y. Xia, L.S. Gresham, C.A. Molgaard, R.G. Thomas, D. Galasko, W.C. Wiederholt, and T. Saitoh

785 Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations
R. Inzelberg, P. Nisipeanu, J.M. Rabey, E. Orlov, T. Catz, S. Kippervasser, E. Schechtman, and A.D. Korczyn

788 Late motor deficits of Chilean manganese miners: A blinded control study
F. Hochberg, G. Miller, R. Valenzuela, S. McNelis, K.S. Crump, T. Covington, G. Valdivia, B. Hochberg, and J.W. Trustman

795 Verbal memory function in mild aphasia
J.E. Ween, M. Verfaellie, and M.P. Alexander

802 The outcome of absence epilepsy: A meta-analysis
P.A.D. Bouma, R.G.J. Westendorp, J.G. van Dijk, A.C.B. Peters, and O.F. Brouwer

Brief Communications

809 Linking estrogen to Alzheimer's disease: An informatics approach
N.R. Smalheiser and D.R. Swanson

810 Hippocampal formation size predicts declining memory performance in normal aging
J. Golomb, A. Kluger, M.J. de Leon, S.H. Ferris, M. Mittelman, J. Cohen, and A.E. George

813 Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome
K.C. Gorson, A.H. Ropper, M.A. Muriello, and R. Blair

817 Autonomic ganglionitis with severe hypertension, migraine, and episodic but fatal hypotension
H.-C. Lee, C.L. Coulter, E.D. Adickes, J. Porterfield, D. Robertson, E. Bravo, and W.A. Pettinger

821 The epilepsy of trisomy 9p
J.M. Stern

824 Global brain dysfunction in an infant with pyridoxine dependency: Evaluation with EEG, evoked potentials, MRI, and PET
J.J. Shih, H. Kornblum, and D.A. Shewmon

827 Spasmodic dysphonia associated with a left ventrolateral putaminal lesion
M.S. Lee, S.B. Lee, and W.C. Kim

Historical Neurology

829 Stages in the recognition of epidemic pellagra in the United States: 1865–1960
D.J. Lanska

Special Articles

835 Practice Advisory: Thrombolytic therapy for acute ischemic stroke—Summary Statement
Report of the Quality Standards Subcommittee of the American Academy of Neurology

840 Assessment of plasmapheresis
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Clinical/Scientific Notes

844 Persistent dyskinesia and obsessive-compulsive behavior following alcohol withdrawal
F. Cardoso and A.P. Vargas

844 Femoral neuropathy from inadvertent suturing of the femoral nerve
J.R. Schottland

845 Spontaneous grammatical corrections in an anomic aphasic
J.E. Shuren, M. Greenwald, and K.M. Heilman

846 Familial hyperlysinemia in a patient presenting with progressive spastic paraparesis
C. Yiannikas and D. Cordato

846 In vivo ^{1}H MRS of brain abscesses versus necrotic brain tumors
S. Grand, E. Sam Laï, F. Estève, Ch. Rubin, D. Hoffmann, C. Rémy, and Ch. Segebarth

Correspondence

849 Erythrocyte thiolmethyltransferase
To the Editor: R.H. Waring, A.C. Williams, and G.B. Steventon. Reply from the Authors: A. Hurwitz and W.C. Koller

850 Fluoxetine and seizures
To the Editor: M.C. Walker and J.W. Sander. Reply from the Authors: C. Albano

850 Recovery from coma
To the Editor: G.Y. Chang and E. Spokoyny. Reply from the Author: L. Bayne

851 Transcranial focal magnetic stimulation in plagiocephaly
To the Editor: R. Coppola and M.S. Myslobodsky. Reply from the Authors: Y. Maegaki

852 Dementia in stroke
To the Editor: H. Hénon, I. Durieu, C. Lucas, O. Godefroy, F. Pasquier, and D. Leys

853 CNS leukemia
To the Editor: P. Duffey, D.J. Burn, R. Cartner, and S.J. Morgan

853 Selective memory loss
To the Editor: L.R. Squire and M. Kritchevsky

854 Yom Kippur headache
To the Editor: J.E. Kundin. Reply from the Author: A.D. Korczyn

854 IFN-secreting cells
To the Editor: T. Olsson and E. Wallström. Reply from the Authors: A.S. Dayal, M.A. Jensen, A. Lledo, and B.G.W. Arnason

Corrections

855 To: Report of the AAN Task Force on access to health care: The effect of no personal health insurance on health care for people with neurologic disorders

855 To: Obsessive-compulsive disorder associated with brain lesions: Clinical phenomenology, cognitive function, and anatomic correlates

Departments

856 Book Reviews

CONTENTS

October 1996 Volume 47 Number 4

Views & Reviews

865 Guidelines for physicians with patients on IFNβ-1b: The use of an assay for neutralizing antibodies (NAB)
D.W. Paty, D. Goodkin, A. Thompson, and G. Rice

866 Ethical use of placebos and provocative testing in diagnosing nonepileptic seizures
O. Devinsky and R. Fisher

871 Classification of daily and near-daily headaches: Field trial of revised IHS criteria
S.D. Silberstein, R.B. Lipton, and M. Sliwinski

876 Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited
J.L. Cummings and D. Kaufer

884 Evolving stroke and the ischemic penumbra
M. Fisher and J.H. Garcia

Articles

889 Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-lb: Experience during the first three years
IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

895 Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis
O. Andersen, J. Lycke, P.O. Tollesson, A. Svenningsson, B. Runmarker, A.S. Linde, M. Åström, P. Gjörstrup, and S. Ekholm

901 Malignant supratentorial glioma in the elderly: Is radiotherapy useful?
S. Meckling, O. Dold, P.A.J. Forsyth, P. Brasher, and N.A. Hagen

906 Intramedullary spinal cord metastases: Clinical features and treatment outcome
D. Schiff and B.P. O'Neill

912 Long-term prognosis of typical childhood absence epilepsy: Remission or progression to juvenile myoclonic epilepsy
E.C. Wirrell, C.S. Camfield, P.R. Camfield, K.E. Gordon, and J.M. Dooley

918 Is the comorbidity of epilepsy and migraine due to a shared genetic susceptibility?
R. Ottman and R.B. Lipton

925 Treatment of Rasmussen's syndrome with ganciclovir
R.S. McLachlan, S. Levin, and W.T. Blume

929 Zoster myelitis: Improvement with antiviral therapy in two cases
S.M. de Silva, A.S. Mark, D.H. Gilden, R. Mahalingam, M. Balish, F. Sandbrink, and S. Houff

932 Motor neuron disease with pyramidal tract dysfunction involves the cortical generators of the early somatosensory evoked potential to tibial nerve stimulation
G. Zanette, M. Tinazzi, A. Polo, and Nicolò Rizzuto

939 Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: An open-labeled trial
S.A. Yablon, B.T. Agana, C.B. Ivanhoe, and C. Boake

944 Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation
P.R. Bergethon, T.D. Sabin, D. Lewis, R.W. Simms, A.S. Cohen, and M. Skinner

951 The sensitivity and specificity of anti-GM_1 antibody testing
B.V. Taylor, L. Gross, and A.J. Windebank

956 Heat-sensitive myotonia in proximal myotonic myopathy
H.W. Sander, G.P. Tavoulareas, and S. Chokroverty

963 Myotonia and the muscle chloride channel: Dominant mutations show variable penetrance and founder effect
P.P. Koty, E. Pegoraro, G. Hobson, H.G. Marks, A. Turel, D. Flagler, M. Cadaldini, C. Angelini, and E.P. Hoffman

969 Reliability of the NINDS Myotatic Reflex Scale
I. Litvan, C.A. Mangone, W. Werden, J.A. Bueri, C.J. Estol, D.O. Garcea, R.C. Rey, R.E.P. Sica, M. Hallett, and J.J. Bartko

973 Function changes in spinal muscular atrophy II and III
B.S. Russman, C.R. Buncher, M. White, F.J. Samaha, S.T. Iannaccone, and the DCN/SMA Group

977 The spectrum of familial inclusion body myopathies in 13 families and a description of a quadriceps-sparing phenotype in non-Iranian Jews
K. Sivakumar and M.C. Dalakas

985 Intestinal pseudo-obstruction, myasthenia gravis, and thymoma
N.E. Anderson, D.O. Hutchinson, G.I. Nicholson, F. Aitcheson, and J.M. Nixon

988 Massive leptomeningeal amyloidosis associated with a Val30Met transthyretin gene
M.K. Herrick, K. DeBruyne, D.S. Horoupian, J. Skare, M.A. Vanefsky, and T. Ong

993 Mutations in the human skeletal muscle chloride channel gene (*CLCN1*) associated with dominant and recessive myotonia congenita
J. Zhang, A.L. George, Jr., R.C. Griggs, G.T. Fouad, J. Roberts, H. Kwieciński, A.M. Connolly, and L.J. Ptáček

999 Intraoperative monitoring of motor evoked potentials: A review of 116 cases
K.J. Nagle, R.G. Emerson, D.C. Adams, E.J. Heyer, D.P. Roye, F.J. Schwab, M. Weidenbaum, P. McCormick, J. Pile-Spellman, B.M. Stein, J.P. Farcy, E.J. Gallo, K.C. Dowling, and C.A. Turner

1004 Effects of stimulus asymmetry on line bisection
S. Chieffi

1009 Angiotropic large-cell lymphoma with peripheral nerve and skeletal muscle involvement: Early diagnosis and treatment
K.H. Levin and G. Lutz

1012 Single large-scale mitochondrial DNA deletion in a patient with mitochondrial myopathy associated with multiple symmetric lipomatosis
Y. Campos, M.A. Martín, C. Navarro, P. Gordo, and J. Arenas

1015 Localization of temporal lobe epileptic foci with iodine-123 iododexetimide cholinergic neuroreceptor single-photon emission computed tomography
K.L. Boundy, C.C. Rowe, A.B. Black, M.I. Kitchener, L.R. Barnden, R. Sebben, A. Kneebone, M. Kassiou, A. Katsifis, and R. Lambrecht

1021 The amygdala and intractable temporal lobe epilepsy: A quantitative magnetic resonance imaging study
W. Van Paesschen, A. Connelly, C.L. Johnson, and J.S. Duncan

1032 Subregional loss of putaminal efferents to the basal ganglia output nuclei may cause parkinsonism in striatonigral degeneration
S. Goto, S. Matsumoto, Y. Ushio, and A. Hirano

1037 Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: Dose-response study and correlations with plasma levels
E.J. Pappert, C.C. Tangney, C.G. Goetz, Z.D. Ling, J.W. Lipton, G.T. Stebbins, and P.M. Carvey

1042 Quantitation of epidermal nerves in diabetic neuropathy
W.R. Kennedy, G. Wendelschafer-Crabb, and T. Johnson

1049 T-cell receptor alpha, beta, gamma, and delta chain gene microsatellites show no association with multiple sclerosis
A.G. Droogan, C.W. Kirk, S.A. Hawkins, S.A. McMillan, N.C. Nevin, and C.A. Graham

1053 Evidence for a prolonged role of α_4 integrin throughout active experimental allergic encephalomyelitis
E. Keszthelyi, S. Karlik, S. Hyduk, G.P.A. Rice, G. Gordon, T. Yednock, and H. Horner

1060 Amyotrophic lateral sclerosis: Oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes
D. Curti, A. Malaspina, G. Facchetti, C. Camana, L. Mazzini, P. Tosca, F. Zerbi, and M. Ceroni

1065 Reduced striatal dopamine receptors in Alzheimer's disease: Single photon emission tomography study with the D_2 tracer [^{123}I]-IBZM
G. Pizzolato, F. Chierichetti, M. Fabbri, A. Cagnin, M. Dam, G. Ferlin, and L. Battistin

1069 Fibroblasts of patients affected by Down's syndrome oversecrete amyloid precursor protein and are hyporesponsive to protein kinase C stimulation
S. Govoni, S. Bergamaschi, L. Gasparini, C. Quaglia, M. Racchi, E. Cattaneo, G. Binetti, A. Bianchetti, F. Giovetti, F. Battaini, and M. Trabucchi

Brief Communications

1076 Good clinical outcome in a patient with a large CT scan hypodensity treated with intra-arterial urokinase after an embolic stroke
R. Tarr, C.L. Taylor, W.R. Selman, J.S. Lewin, and D. Landis

1079 Nonconvulsive status epilepticus in thrombotic thrombocytopenic purpura
A.S. Blum and F.W. Drislane

1081 Spinal cord venous infarction following endoscopic sclerotherapy for esophageal varices
S.L. Heller, J.R. Meyer, and E.J. Russell

1085 Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
E.Ch. Wolters, E.N.H. Jansen, H.G. Tuynman-Qua, and P.L.M. Bergmans

1088 Regional subacute cranial neuropathies following internal carotid cisplatin infusion
L.M. Alderson, P.T. Noonan, I.S. Choi, and J.W. Henson

1090 Anterior choroidal artery aneurysm and stroke
L.B. Morgenstern, L.L. Hankins, and J.C. Grotta

1093 Elevation of cerebral lactate detected by localized ^{1}H-magnetic resonance spectroscopy in migraine during the interictal period
H. Watanabe, T. Kuwabara, M. Ohkubo, S. Tsuji, and T. Yuasa

Historical Neurology

1096 Neurology's witness to history: The Combined Intelligence Operative Sub-Committee Reports of Leo Alexander
M.I. Shevell

Clinical/Scientific Notes

1104 Use of sumatriptan in post-ictal migraine headache
J. Jacob, P.J. Goadsby, and J.S. Duncan

1104 Exquisite sensitivity of paroxysmal kinesigenic choreoathetosis to carbamazepine
T. Wein, F. Andermann, K. Silver, F. Dubeau, E. Andermann, F. Rourke-Frew, and D. Keene

1106 Gabapentin interaction with felbamate
G. Hussein, A.S. Troupin, and G. Montouris

1106 Nine families with the SCA3/Machado-Joseph disease type of inherited ataxia
P.E. Greenstein, D. Moore, E. Levy-Lahad, K. Stephens, and T.D. Bird

Correspondence

1108 Worth of neurologists
To the Editor: M.A. Whelan. To the Editor: W.J. Weiner and L.M. Shulman. Reply from the Authors: M.E. Hillen and J.I. Sage

1108 Spinal A-V fistula
To the Editor: W. Nacimiento and A. Thron. Reply from the Authors: R.W. Hurst, L.C. Kenyon, E. Lavi, E.C. Raps, and P. Marcotte

1109 Risk factors for lacunes
To the Editor: J. Boiten, G.-J. Luijckx, F. Kessels, and J. Lodder. Reply from the Authors: R.X. You, J.J. McNeil, S.M. Davis, and G.A. Donnan

1110 IFNB in MS
To the Editor: L.A. Rolak. To the Editor: D. Barnes. To the Editor: C. Milanese, G. Savettieri, and E. Terzian. Replies from the Authors: W.A. Sibley, D. Paty, G. Ebers, A. Reder, and F. Lublin

---

November 1996 Volume 47 Number 5

View & Review

1113 Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
I.G. McKeith, D. Galasko, K. Kosaka, E.K. Perry, D.W. Dickson, L.A. Hansen, D.P. Salmon, J. Lowe, S.S. Mirra, E.J. Byrne, G. Lennox, N.P. Quinn, J.A. Edwardson, P.G. Ince, C. Bergeron, A. Burns, B.L. Miller, S. Lovestone, D. Collerton, E.N.H. Jansen, C. Ballard, R.A.I. de Vos, G.K. Wilcock, K.A. Jellinger, and R.H. Perry, for the Consortium on Dementia with Lewy Bodies

Articles

1125 Arterial territories of human brain: Brainstem and cerebellum
L. Tatu, T. Moulin, J. Bogousslavsky, and H. Duvernoy

1135 Dysarthria and lacunar stroke: Pathophysiologic aspects
P.P. Urban, H.C. Hopf, P.G. Zorowka, S. Fleischer, and J. Andreas

1141 Medial medullary infarction: Analyses of eleven patients
K. Toyoda, T. Imamura, Y. Saku, J. Oita, S. Ibayashi, K. Minematsu, T. Yamaguchi, and M. Fujishima

1148 Psychiatric features in diffuse Lewy body disease: A clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups
L.A. Klatka, E.D. Louis, and R.B. Schiffer

1153 Low-dose oral methotrexate in chronic progressive multiple sclerosis: Analyses of serial MRIs
D.E. Goodkin, R.A. Rudick, S. VanderBrug Medendorp, M.M. Daughtry, and C. Van Dyke

1158 Long-term prognosis and the effect of carotid endarterectomy in patients with recurrent ipsilateral ischemic events
L.M. Paddock-Eliasziw, M. Eliasziw, H.W.K. Barr, and H.J.M. Barnett, for the North American Symptomatic Carotid Endarterectomy Trial Group

1162 Prognosis after stroke followed by surgical closure of patent foramen ovale: A prospective follow-up study with brain MRI and simultaneous transesophageal and transcranial Doppler ultrasound
G. Devuyst, J. Bogousslavsky, P. Ruchat, X. Jeanrenaud, P.-A. Despland, F. Regli, N. Aebischer, H.M. Karpuz, V. Castillo, M. Guffi, and H. Sadeghi

1167 Sleep apnea in patients with transient ischemic attack and stroke: A prospective study of 59 patients
C. Bassetti, M.S. Aldrich, R.D. Chervin, and D. Quint

1173 Sleep and neuromuscular disease: Frequency of sleep-disordered breathing in a neuromuscular disease clinic population
M. Labanowski, W. Schmidt-Nowara, and C. Guilleminault

1180 Nonmotor fluctuations in patients with Parkinson's disease
M.E. Hillen and J.I. Sage

1184 Neuropsychiatric aspects of progressive supranuclear palsy
I. Litvan, M.S. Mega, J.L. Cummings, and L. Fairbanks

1189 Frontotemporal dementia versus Alzheimer's disease: Differential cognitive features
M.F. Mendez, M. Cherrier, K.M. Perryman, N. Pachana, B.L. Miller, and J.L. Cummings

1194 Cross-national interrater reliability of dementia diagnosis in the elderly and factors associated with disagreement
D.W. O'Connor, G. Blessed, B. Cooper, C. Jonker, J.C. Morris, I.B. Presnell, D. Ames, D.W.K. Kay, H. Bickel, M. Schäufele, A. Wind, M. Coats, and L. Berg

1199 Characteristics of temporal lobe epilepsy with mesial temporal sclerosis, with special reference to psychotic episodes
K. Kanemoto, J. Takeuchi, J. Kawasaki, and I. Kawai

1203 Visual working memory in primary generalized epilepsy: An ^{18}FDG-PET study
B.E. Swartz, F. Simpkins, E. Halgren, M. Mandelkern, C. Brown, T. Krisdakumtorn, and M. Gee

1213 Postpartum neuralgic amyotrophy
R.J. Lederman and A.J. Wilbourn

1220 A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data
R. Tandan, M.B. Bromberg, D. Forshew, T.J. Fries, G.J. Badger, J. Carpenter, P.B. Krusinski, E.F. Betts, K. Arciero, and K. Nau

1227 Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance
N.C. Notermans, H.M. Lokhorst, H. Franssen, Y. Van der Graaf, L.L. Teunissen, F.G.I. Jennekens, L.H. Van den Berg, and J.H.J. Wokke

1233 Epidemiologic evidence for a changing natural history of myasthenia gravis
L.H. Phillips II and J.C. Torner

1239 Stimulus-evoked sinus arrest in severe Guillain-Barré syndrome: A case report
R.E. Minahan, Jr., A. Bhardwaj, T.A. Traill, and D.F. Hanley

1243 Contraction response to muscle percussion is increased in peripheral nerve conduction block
M.R. Magistris and A. Kohler

1247 Clinical confirmation of the American Academy of Neurology algorithm for HIV-1–associated cognitive/motor disorder
The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders

1254 Peptide T in the treatment of painful distal neuropathy associated with AIDS: Results of a placebo-controlled trial
D.M. Simpson, D. Dorfman, R.K. Olney, G. McKinley, J. Dobkin, Y. So, J. Berger, M.B. Ferdon, B. Friedman, and The Peptide T Neuropathy Study Group

1260 Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease: A retrospective study on 119 patients
G. De Michele, F. Perrone, A. Filla, E. Mirante, M. Giordano, S. De Placido, and G. Campanella

1264 Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with *N*-acetylcysteine
R.W. Hurd, B.J. Wilder, W.R. Helveston, and B.M. Uthman

1269 Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations
M.E. Baser, V.-F. Mautner, N.K. Ragge, A. Nechiporuk, V.M. Riccardi, J. Klein, J. Sainz, and S.-M. Pulst

1278 MRI findings in subacute sclerosing panencephalitis
B. Anlar, I. Saatçi, G. Köse, and K. Yalaz

1284 Lenticular nucleus lesion in idiopathic dystonia detected by transcranial sonography
M. Naumann, G. Becker, K.V. Toyka, T. Supprian, and K. Reiners

1291 Striatal efferent involvement and its correlation to levodopa efficacy in patients with multiple system atrophy
H. Ito, H. Kusaka, S. Matsumoto, and T. Imai

1299 Central conduction in somatosensory evoked potentials: Comparison of ulnar and median data and evaluation of onset versus peak methods
I. Ozaki, H. Takada, H. Shimamura, M. Baba, and M. Matsunaga

1305 Mutation of the prion protein gene at codon 208 in familial Creutzfeldt-Jakob disease
J.A. Mastrianni, C. Iannicola, R.M. Myers, S. DeArmond, and S.B. Prusiner

1313 Fatal familial insomnia with a mutation at codon 178 of the prion protein gene: First report from Japan
M. Nagayama, Y. Shinohara, H. Furukawa, and T. Kitamoto

1317 Selective staining of the cerebellar molecular layer by serum IgG in Miller-Fisher and related syndromes
A.J. Kornberg, A. Pestronk, G.M. Blume, G. Lopate, J. Yue, and A. Hahn

1320 Leigh-type neuropathology in Pearson syndrome associated with impaired ATP production and a novel mtDNA deletion
F.M. Santorelli, M.A. Barmada, R. Pons, L.L. Zhang, and S. DiMauro

Brief Communications

1324 Can tropicamide eye drop response differentiate patients with progressive supranuclear palsy and Alzheimer's disease from healthy control subjects?
I. Litvan and E.J. FitzGibbon

1326 Fatal familial insomnia: A seventh family
P. Silburn, L. Cervenáková, P. Varghese, A. Tannenberg, P. Brown, and R. Boyle

1329 Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis
R.G. Miller, W.W. Bryan, M.A. Dietz, T.L. Munsat, J.H. Petajan, S.A. Smith, and J.C. Goodpasture

1331 Methazolamide for essential voice tremor
K. Busenbark, L. Ramig, C. Dromey, and W.C. Koller

1333 Adult-onset neurodegenerative disorder due to proteolipid protein gene mutation in the mother of a man with Pelizaeus-Merzbacher disease
M.A. Nance, S. Boyadjiev, V.M. Pratt, S. Taylor, M.E. Hodes, and S.R. Dlouhy

1336 D90A heterozygosity in the *SOD1* gene is associated with familial and apparently sporadic amyotrophic lateral sclerosis
W. Robberecht, T. Aguirre, L. Van Den Bosch, P. Tilkin, J.J. Cassiman, and G. Matthijs

1339 Noninvasive perfusion MRI in Alzheimer's disease: A preliminary report
T.A. Sandson, M. O'Connor, R.A. Sperling, R.R. Edelman, and S. Warach

Special Article

1343 Practice Parameter: Genetic testing alert
Statement of the Practice Committee Genetics Testing Task Force of the American Academy of Neurology

In Memoriam

1345 James Kiffin Penry (1929–1996)
R.J. Porter

Clinical/Scientific Notes

1347 Treatment-refractory cyclosporine-associated headache: Relief with conversion to FK-506
T.D. Rozen, E.F.M. Wijdicks, and J.E. Hay

1347 "Picture within a picture" visual hallucinations
N.M. Benegas, G.T. Liu, N.J. Volpe, and S.L. Galetta

1348 Ataxic hemiparesis and hemiageusia from an isolated post-traumatic midbrain lesion
T.M. Johnson

1349 The 5-repeat allele in the very-low-density lipoprotein receptor gene polymorphism is not increased in sporadic Alzheimer's disease in Japanese
T. Arinami, K. Takekoshi, H. Yanagi, M. Hamamoto, and H. Hamaguchi

Correspondence

1351 Grievous bodily harm
To the Editor: E.J. Carrazana

1351 Fatigue in MS
To the Editor: C.M. Poser. To the Editor: D. Dulli and H. Schutta. Reply from the Authors: L.B. Krupp, P.K. Coyle, R. Grimson, A. Miller, and A.H. Cross

1352 Hering's law for eyelids
To the Editor: E. Eggenberger and N. Kayabasi. Reply from the Authors: L. Averbuch-Heller

1352 Apolipoprotein E
To the Editor: G.B. Frisoni, A. Bianchetti, and M. Trabucchi. Reply from the Authors: M.C. Tierney and J.P. Szalai

1353 Breast implants
To the Editor: J.S. Grisolia. Reply from the Author: N.L. Rosenberg

1355 MR and chemotherapy
To the Editor: Y. Miaux, P. Ribaud, A. Weill, N. Martin-Duverneuil, C. Cognard, D. Savin, and J. Chiras

1355 Neurocysticercosis
To the Editor: L.M. Monteiro and A. Pinto, Jr.

1355 Vagal stimulation
To the Editor: H. Uysal, L.E. İnan, and P. Kuli

1356 Expert witness testimony
To the Editor: M.I. Weintraub

1356 Intent-to-treat
To the Editor: G.W. Pledger. Reply from the Authors: V.S. Shu and L.J. Willmore

1357 Stroke and cardiac arrest
To the Editor: J.H. Jaster, L.M. Porterfield, T.E. Bertorini, F.C. Dohan, Jr., and T. Becske

1357 Gender and AD
To the Editor: R. Heun, W. Maier, and H. Müller. Reply from the Author: H. Payami

1358 Delayed-onset dyskinesias
To the Editor: S. Przedborski, V.N. Kostic, and R.E. Burke. Reply from the Authors: B.L. Scott and J. Jankovic

1359 Post-polio syndrome
To the Editor: R.L. Bruno. Reply from the Author: A.J. Windebank

Correction

1360 To: Book review of "Clinical Neurology for Psychiatrists"

CONTENTS

December 1996 Volume 47 Number 6

1361 Message from the editor's office

Editorials

1365 A decade ends: The editor leaves
R.B. Daroff

1368 The fourth editor-in-chief of **Neurology**: Robert C. Griggs
R.J. Joynt

1370 Could treatment with DOPS do for autonomic failure what DOPA did for Parkinson's disease?
H. Kaufmann

Views & Reviews

1372 See-saw nystagmus in dogs and humans: An international, across-discipline, serendipitous collaboration
L.F. Dell'Osso

1374 Hypomanic symptoms caused by herpes simplex encephalitis
C.M. Fisher

1379 Benchmarking graduate medical education in neurology: A cross-specialty comparison and analysis of residency matching data
D.J. Iverson

Articles

1383 Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis
R.G. Miller, D. Moore, L.A. Young, C. Armon, R.J. Barohn, M.B. Bromberg, W.W. Bryan, D.F. Gelinas, M.C. Mendoza, H.E. Neville, G.J. Parry, J.H. Petajan, J.M. Ravits, S.P. Ringel, M.A. Ross, and the WALS Study Group

1389 A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease
L.J. Thal, G. Schwartz, M. Sano, M. Weiner, D. Knopman, L. Harrell, S. Bodenheimer, M. Rossor, M. Philpot, J. Schor, A. Goldberg, for the Physostigmine Study Group

1396 The effect on memory of chronic prednisone treatment in patients with systemic disease
P.A. Keenan, M.W. Jacobson, R.M. Soleymani, M.D. Mayes, M.E. Stress, and D.T. Yaldoo

1403 Dementia with Lewy bodies: Reliability and validity of clinical and pathologic criteria
M.S. Mega, D.L. Masterman, D.F. Benson, H.V. Vinters, U. Tomiyasu, A.H. Craig, D.J. Foti, D. Kaufer, D.W. Scharre, L. Fairbanks, and J.L. Cummings

1410 Decreased postexercise facilitation of motor evoked potentials in patients with chronic fatigue syndrome or depression
A. Samii, E.M. Wassermann, K. Ikoma, B. Mercuri, M.S. George, A. O'Fallon, J.K. Dale, S.E. Straus, and M. Hallett

1414 The treatment of postprandial hypotension in autonomic failure with 3,4-DL-threo-dihydroxyphenylserine
R. Freeman, J. Young, L. Landsberg, and L. Lipsitz

1420 A population-based model of risk factors for ischemic stroke: Rochester, Minnesota
J.P. Whisnant, D.O. Wiebers, W.M. O'Fallon, J.D. Sicks, and R.L. Frye

1429 Relevance of early seizures for in-hospital mortality in acute cerebrovascular disease
A. Arboix, E. Comes, J. Massons, L. García, and M. Oliveres

1435 Restless legs syndrome: Clinicoetiologic correlates
W. Ondo and J. Jankovic

1441 Varicella zoster virus, a cause of waxing and waning vasculitis: The *New England Journal of Medicine* case 5-1995 revisited
D.H. Gilden, B.K. Kleinschmidt-DeMasters, M. Wellish, E.T. Hedley-Whyte, B. Rentier, and R. Mahalingam

1446 Painful vasculitic neuropathy in HIV-1 infection: Relief of pain with prednisone therapy
W.G. Bradley and A. Verma

1452 Pattern electroretinograms and visual evoked potentials in HIV infection: Evidence of asymptomatic retinal and postretinal impairment in the absence of infectious retinopathy
V.J. Iragui, J. Kalmijn, D.J. Plummer, P.A. Sample, G.L. Trick, and W.R. Freeman

1457 Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial
C.T. Bever, Jr., P.A. Anderson, J. Leslie, H.S. Panitch, S. Dhib-Jalbut, O.A. Khan, R. Milo, J.R. Hebel, K.L. Conway, E. Katz, and K.P. Johnson

1463 Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon β-1b
N.H. Pliskin, D.P. Hamer, D.S. Goldstein, V.L. Towle, A.T. Reder, A. Noronha, and B.G.W. Arnason

1469 Accumulation of hypointense lesions ("black holes") on T_1 spin-echo MRI correlates with disease progression in multiple sclerosis
L. Truyen, J.H.T.M. van Waesberghe, M.A.A. van Walderveen, B.W. van Oosten, C.H. Polman, O.R. Hommes, H.J.A. Adèr, and F. Barkhof

1477 Elevated risk of Alzheimer's disease among workers with likely electromagnetic field exposure
E. Sobel, M. Dunn, Z. Davanipour, Z. Qian, and H.C. Chui

1482 Prosody impairment and associated affective and behavioral disturbances in Alzheimer's disease
V.J. Roberts, S.M. Ingram, M. Lamar, and R.C. Green

1488 Post-traumatic movement disorders in survivors of severe head injury
J.K. Krauss, R. Tränkle, and K.-H. Kopp

1493 Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation
E.J. Pappert, C.G. Goetz, F. Niederman, Z.D. Ling, G.T. Stebbins, and P.M. Carvey

1496 Intensive speech treatment for patients with Parkinson's disease: Short- and long-term comparison of two techniques
L.O. Ramig, S. Countryman, C. O'Brien, M. Hoehn, and L. Thompson

1504 Recovery from nonfluent aphasia after melodic intonation therapy: A PET study
P. Belin, Ph. Van Eeckhout, M. Zilbovicius, Ph. Remy, C. François, S. Guillaume, F. Chain, G. Rancurel, and Y. Samson

1512 Anticipation in familial Parkinson's disease: A reanalysis of 13 United Kingdom kindreds
D.M. Maraganore, D.J. Schaid, W.A. Rocca, and A.E. Harding

1518 Clozapine-induced myotoxicity in patients with chronic psychotic disorders
S.N. Scelsa, D.M. Simpson, H.L. McQuistion, A. Fineman, K. Ault, and B. Reichler

1523 Causes and outcome of seizures in liver transplant recipients
E.F.M. Wijdicks, D.J. Plevak, R.H. Wiesner, and J.L. Steers

1526 Neurospectroscopic alterations and globus pallidus hyperintensity as related magnetic resonance markers of reversible hepatic encephalopathy
J. Pujol, J. Kulisevsky, A. Moreno, J. Deus, J. Alonso, J. Balanzó, J.L. Martí-Vilalta, and A. Capdevila

1531 Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
B.W. van Oosten, F. Barkhof, L. Truyen, J.B. Boringa, F.W. Bertelsmann, B.M.E. von Blomberg, J.N. Woody, H.-P. Hartung, and C.H. Polman

1535 Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: Correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings
M. Trojano, C. Avolio, I.L. Simone, G. Defazio, C. Manzari, F. De Robertis, A. Calò, and P. Livrea

1542 T-cell subpopulations in the cerebrospinal fluid and peripheral blood of patients with multiple sclerosis: A follow-up study
O. Oksaranta, S. Tarvonen, J. Ilonen, K. Poikonen, M. Reunanen, M. Panelius, and R. Salonen

1546 Nigrostriatal dopaminergic function in familial amyotrophic lateral sclerosis patients with and without copper/zinc superoxide dismutase mutations
S. Przedborski, V. Dhawan, D.M. Donaldson, P.L. Murphy, D. McKenna-Yasek, F.S. Mandel, R.H. Brown, Jr., and D. Eidelberg

1552 A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis
D. Beeson, L. Jacobson, J. Newsom-Davis, and A. Vincent

1555 Reduced corticomotoneuronal excitatory postsynaptic potentials (EPSPs) with normal Ia afferent EPSPs in amyotrophic lateral sclerosis
M. Nakajima, A. Eisen, R. McCarthy, R.K. Olney, and M.J. Aminoff

1562 Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly)
F. Garzuly, T. Wisniewski, F. Brittig, and H. Budka

1567 Human brain GABA levels rise rapidly after initiation of vigabatrin therapy
O.A.C. Petroff, D.L. Rothman, K.L. Behar, T.L. Collins, and R.H. Mattson

1571 Proton magnetic resonance spectroscopy of a gray matter heterotopia
L. Marsh, K.O. Lim, E.V. Sullivan, B. Lane, and D. Spielman

1575 Lack of association between α1-antichymotrypsin polymorphism, Alzheimer's disease, and allele ϵ4 of apolipoprotein E
U. Müller, R.-H. Bödeker, I. Gerundt, and A. Kurz

Brief Communications

1578 Diagnosis of patients presenting to a Huntington disease (HD) clinic without a family history of HD
M.A. Nance, B. Westphal, and S. Nugent

1581 Brain morphometry in Tourette's syndrome: The influence of comorbid attention-deficit/hyperactivity disorder
F.X. Castellanos, J.N. Giedd, S.D. Hamburger, W.L. Marsh, and J.L. Rapoport

1583 Levodopa therapy improves motor function in HIV-infected children with extrapyramidal syndromes
M. Mintz, M. Tardieu, L. Hoyt, G. McSherry, J. Mendelson, and J. Oleske

1586 Comparing composite scores based on maximal voluntary isometric contraction and on semiquantitative manual motor testing in measuring limb strength in patients with ALS
C. Armon and E. Ponraj

1588 Presynaptic nigrostriatal function in genetically tested asymptomatic relatives from the pallido-ponto-nigral degeneration family
A. Kishore, Z.K. Wszolek, B.J. Snow, R. de la Fuente-Fernandez, F. Arwert, M. Wijker, M. Schulzer, D.B. Calne, and F.J.G. Vingerhoets

1590 Optimum stimulus parameters for lateralized suppression of speech with magnetic brain stimulation
C.M. Epstein, J.J. Lah, K. Meador, J.D. Weissman, L.E. Gaitan, and B. Dihenia

Hypothesis

1594 Electromagnetic field exposure may cause increased production of amyloid beta and eventually lead to Alzheimer's disease
E. Sobel and Z. Davanipour

Clinical/Scientific Notes

1601 Cranial nerve enhancement on three-dimensional MRI in Miller Fisher syndrome
U. Nagaoka, T. Kato, K. Kurita, S. Arawaka, T. Hosoya, N. Yuki, Y. Shikama, K. Yamaguchi, and H. Sasaki

1602 Pseudotumor cerebri and cerebral venous hypertension
P.D. Cremer, E.O. Thompson, I.H. Johnston, and G. Michael Halmagyi

1604 Healthy infant delivered by a mother with subacute sclerosing panencephalitis during pregnancy
A. Thiel, R. Nau, F. Fischer, H. Meden, K. Harms, B. Weißbrich, and H. Prange

1604 Taste loss as an initial symptom of Guillain-Barré syndrome
O. Combarros, J. Pascual, C. de Pablos, F. Ortega, and J. Berciano

Correspondence

1606 Liver function in GBS
To the Editor: R.P. Lisak. Reply from the Authors: P.G. Oomes, P.A. van Doorn, and F.G.A. van der Meché

1606 Recurrent inhibition
To the Editor: R. Mazzocchio and A. Rossi. Reply from the Author: R.R. Young

1608 Valproate toxicity
To the Editor: J. Parra, J. Iriarte, and S.J.C. Pierre-Louis. Reply from the Authors: A.E. Bryant III and F.E. Dreifuss

1608 Ondansetron treatment of L-dopa-induced psychosis
To the Editor: T.E. Eichhorn, E. Brunt, and W.H. Oertel. Reply from the Authors: J. Zoldan and G. Friedberg

1610 Post-polio neuromuscular symptoms
To the Editor: H.W. Sander and H. Bartfeld. Reply from the Authors: A.J. Windebank

1610 Neurology and murderers
To the Editor: A. Di Rocco. To the Editor: D. Montie. To the Editor: R.A. Burton. Reply from the Authors: P. Blake and J. Pincus

1611 The dying patient
To the Editor: W.J. Burke. Reply from the Authors: J.L. Bernat, M.L. Goldstein, and K.M. Viste, Jr.

CONTENTS

Departments

1613 Book Reviews

1616 Subject index to volume 47

1641 Author index to volume 47

i Contents to volume 47

July 1996 Volume 47 Suppl 1

Introduction

1 Use of vigabatrin in epilepsy
R.A. Mackenzie

Articles

2 Newer antiepileptic drugs as monotherapy: Data on vigabatrin
R. Fisher, R. Kälviäinen, P. Tanganelli, and G. Regesta

6 Cognitive effects of vigabatrin: A review
F. Monaco

12 Treatment with antiepileptic drugs: Possible neuroprotective effects
A. Pitkänen

October 1996 Volume 47 Suppl 2

Introduction

S17 Advances in ALS
L. Gutmann and H. Mitsumoto

Pathogenesis

S19 Excitotoxicity hypothesis
J.D. Rothstein

S27 Molecular genetic basis of familial ALS
T. Siddique, D. Nijhawan, and A. Hentati

S36 Cell death mechanisms in ALS
D.E. Bredesen, M. Wiedau-Pazos, J.J. Goto, S. Rabizadeh, J.A. Roe, E.B. Gralla, L.M. Ellerby, and J.S. Valentine

S40 Autoimmunity and ALS
R.G. Smith, L. Siklos, M.E. Alexianu, J.I. Engelhardt, D.R. Mosier, L. Colom, A. Habib Mohamed, and S.H. Appel

S47 Motor neuron growth factors
J.L. Elliott and W.D. Snider

S54 Mechanisms of selective motor neuron death in transgenic mouse models of motor neuron disease
D.W. Cleveland, L.I. Bruijn, P.C. Wong, J.R. Marszalek, J.D. Vechio, M.K. Lee, X.-S. Xu, D.R. Borchelt, S.S. Sisodia, and D.L. Price

S63 Neuropathology of ALS: An overview
A. Hirano

Clinical trials and future research

S67 Diagnostic criteria in clinical trials
M.H. Brooke

S71 Natural history of ALS: Symptoms, strength, pulmonary function, and disability
B.R. Brooks

S83 Development of measurement techniques
T.L. Munsat

S86 Clinical trials of riluzole in patients with ALS
R.G. Miller, J.P. Bouchard, P. Duquette, A. Eisen, D. Gelinas, Y. Harati, T.L. Munsat, L. Powe, J. Rothstein, P. Salzman, R.L. Sufit, and the ALS/Riluzole Study Group-II

S93 Recombinant human insulin-like growth factor-I in ALS: Description of a double-blind, placebo-controlled study
D.J. Lange, K.J. Felice, B.W. Festoff, M.J. Gawel, D.F. Gelinas, R. Kratz, E.C. Lai, M.F. Murphy, H.M. Natter, F.H. Norris, S. Rudnicki, and the North American ALS/IGF-I Study Group

S96 Issues in clinical trial design I: Use of natural history controls. A protagonist view
T.L. Munsat

S98 Issues in clinical trial design I: Use of natural history controls. An antagonist view
R.L. Sufit

S100 Issues in clinical trial design II: Selection of end point measures
M.B. Bromberg and B.R. Brooks

S103 Drug combination treatment in patients with ALS: Current status and future directions
H. Mitsumoto and R.K. Olney

S108 Advances in ALS Workshop Summary: Research and future goals
M.H. Brooke and M.J. Strong

ALS patient care issues

S113 ALS CARE: A resource for measuring and improving ALS outcomes
F.A. Anderson, Jr., R.G. Miller, and members of the ALS CARE Advisory Board

S117 The impact of the approval of riluzole
R. Sufit and D. Newman

S118 Management of ALS: Nutritional care
E.J. Kasarskis and H.E. Neville

S121 Improving education for physicians and for patients
D.A. Chad and R.G. Miller

S123 Management of ALS: Respiratory care
L.C. Hopkins, G.T. Tatarian, and T.F. Pianta

S126 The economic impact of ALS
L.M. Klein and D.A. Forshew

Panel discussion

S130 Communications and ALS trial: Information sharing

December 1996 Volume 47 Number 3

Articles

S137 Pharmacology of selegiline
M. Gerlach, M.B.H. Youdim, and P. Riederer

S146 The natural history of Parkinson's disease
W.H. Poewe and G.K. Wenning

S153 The etiology of Parkinson's disease with emphasis on the MPTP story
J.W. Langston

S161 Oxidative stress and the pathogenesis of Parkinson's disease
P. Jenner and C.W. Olanow

S171 Modulation of gene expression rather than monamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration
W.G. Tatton and R.M.E. Chalmers-Redman

S184 Is levodopa toxic?
S. Fahn

S196 Selegiline monotherapy in the treatment of Parkinson's disease
W.C. Koller

S200 Role of selegiline in combination therapy of Parkinson's disease
V.V. Myllylä, K. Sotaniemi, O. Mäki-Ikola, U.K. Rinne, and E.H. Heinonen

S210 Selegiline: Current perspectives on issues related to neuroprotection and mortality
C.W. Olanow

CONTENTS

December 1996 Volume 47 Number 4

Introduction

S217 Therapeutic advances in ALS
R. Miller and M. Swash

Articles

S218 ALS
F. Jerusalem, Ch. Pohl, J. Karitzky, and F. Ries

S221 Excitotoxicity in ALS
P.N. Leigh and B.S. Meldrum

S228 Animal models for motor neuron diseases: Research directions
A.C. Ludolph

S233 The pharmacology and mechanism of action of riluzole
A. Doble

S242 A confirmatory dose-ranging study of riluzole in ALS
L. Lacomblez, G. Bensimon, P.N. Leigh, P. Guillet, L. Powe, S. Durrleman, J.C. Delumeau, V. Meininger, and the ALS/Riluzole Study Group-II

S251 ALS therapy: Targets for the future
J. Hugon